Want to see AU:SOM full AI Analyst Report?
Top Page
Somnomed Limited
(Sydney:SOM)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$0.30
â–Ľ(-10.00% Downside)
Action:Reiterated
Date:10/16/26
Overall score reflects improving underlying operations and cash generation with a strengthened balance sheet, but tempered by continued net losses and negative ROE. Technical signals are notably weak with the stock trading below major moving averages and bearish momentum indicators. Guidance is cautiously positive, yet meaningful regional (Europe) and FX headwinds plus product roadmap uncertainty limit conviction.
Positive Factors
EBITDA growth and margin expansion
Improving EBITDA and margins indicate stronger operating leverage from better gross margin and disciplined costs. If maintained, this provides greater capacity to fund product development, absorb regional volatility, and convert revenue growth into more durable earnings over the next several quarters.
Negative Factors
Structural European access headwinds
European reimbursement and access changes affect how patients are identified, referred, and funded, making the company’s largest region harder to grow predictably. These structural issues may require sustained commercial adaptation and could constrain revenue and margin progress over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
EBITDA growth and margin expansion
Improving EBITDA and margins indicate stronger operating leverage from better gross margin and disciplined costs. If maintained, this provides greater capacity to fund product development, absorb regional volatility, and convert revenue growth into more durable earnings over the next several quarters.
Read all positive factors
Somnomed Limited (SOM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$51.65M
Dividend YieldN/A
Average Volume (3M)62.21K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth2.73%
EPS Growth25.00%
CountryAU
Employees300
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,768,250
10 Day Avg. Volume63,379
30 Day Avg. Volume62,213
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)2.37
Price to Sales (P/S)0.98
P/FCF Ratio22.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.76Price Target Upside130.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Somnomed Limited Business Overview & Revenue Model
Company Description
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDe...
How the Company Makes Money
SomnoMed primarily makes money by selling medical devices—custom oral appliances used to treat OSA and snoring—through a prescription-based clinical workflow. Revenue is generated when a sleep physician (or other qualified clinician) diagnoses OSA...
Somnomed Limited Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
71
Positive
Cash Flow
66
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 114.53M | 111.49M | 91.65M | 83.62M | 72.58M |
| Gross Profit | 60.91M | 66.73M | 55.13M | 45.77M | 39.15M |
| EBITDA | 6.46M | 5.44M | -2.33M | 698.39K | 524.53K |
| Net Income | -2.65M | -3.46M | -12.24M | -8.00M | -4.44M |
Balance Sheet | |||||
| Total Assets | 75.00M | 80.97M | 69.80M | 62.49M | 58.09M |
| Cash, Cash Equivalents and Short-Term Investments | 17.18M | 17.29M | 16.18M | 11.96M | 15.64M |
| Total Debt | 5.46M | 8.03M | 6.72M | 23.51M | 12.01M |
| Total Liabilities | 27.60M | 34.58M | 24.78M | 40.09M | 30.31M |
| Stockholders Equity | 47.40M | 46.39M | 45.02M | 22.40M | 27.79M |
Cash Flow | |||||
| Free Cash Flow | 5.02M | 5.36M | -7.72M | -10.29M | -6.93M |
| Operating Cash Flow | 8.28M | 7.78M | -6.33M | -3.88M | 1.86M |
| Investing Cash Flow | -5.74M | -3.98M | -5.34M | -6.41M | -8.47M |
| Financing Cash Flow | -1.47M | -3.38M | 16.68M | 6.61M | 2.09M |
Somnomed Limited Technical Analysis
Neutral
0.33
Price Trends
0.32
Negative
0.41
Negative
0.52
Negative
Market Momentum
-0.02
Negative
50.00
Neutral
28.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SOM, the sentiment is Neutral. The current price of 0.33 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.32, and below the 200-day MA of 0.52, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.00 is Neutral, neither overbought nor oversold. The STOCH value of 28.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:SOM.
Somnomed Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$9.12B | 62.45 | 8.01% | 2.44% | -0.90% | -62.14% | |
57 Neutral | AU$48.94M | 218.18 | 0.93% | ― | 18.54% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | AU$51.65M | -23.97 | -5.44% | ― | 2.73% | 25.00% | |
55 Neutral | AU$2.31B | -9.67 | -288.42% | ― | 20.64% | -457.40% | |
50 Neutral | AU$43.64M | -4.06 | -188.06% | ― | 15.58% | 37.17% | |
41 Neutral | AU$46.52M | -2.31 | -62.14% | 0.64% | 12.05% | -31.71% |
* General Sector Average
AU:SOM
Somnomed Limited
0.29
-0.59
-67.05%
AU:COH
Cochlear
140.59
-144.30
-50.65%
AU:CMP
Compumedics Limited
0.24
-0.11
-32.39%
AU:CYC
Cyclopharm Limited
0.36
-0.30
-45.04%
AU:MX1
Micro-X Ltd.
0.06
-0.04
-42.00%
AU:4DX
4DMedical Ltd
3.77
1.79
90.40%
Somnomed Limited Corporate Events
SomnoMed Options Lapse Alters Future Capital Structure
Sep 4, 2026
SomnoMed Limited has announced the cessation of 77,000 SOMAP options, which were due to expire on 31 August 2027 at an exercise price of $2.33, after the conditional rights attached to these securities lapsed because the required conditions were n...
SomnoMed Director Russo Sees Reduction in Options After Lapse
Aug 28, 2026
SomnoMed Limited has reported a change in the interests of director Gaetano Alfred Gerrard Russo, whose holdings are held indirectly through a self-managed superannuation fund. Prior to the change, the fund held 2,055,220 ordinary fully paid share...
SomnoMed Discloses Lapse of Director Michael Gordon’s Options
Aug 28, 2026
SomnoMed Limited has disclosed a change in director Michael Gordon’s interests in the company’s securities, reflecting the lapse of a portion of his options held via a superannuation structure. Gordon retains his indirect shareholding ...
SomnoMed Tightens Insider Trading Rules With New Securities Policy
Aug 27, 2026
SomnoMed Limited operates in the medical devices sector, focusing on oral appliance therapies for the treatment of sleep-related breathing disorders such as obstructive sleep apnea. The company targets patients, clinicians, and sleep specialists i...
SomnoMed Outlines Board Oversight and Governance Framework Under ASX Principles
Aug 27, 2026
SomnoMed has detailed its corporate governance framework in line with the latest ASX Corporate Governance Principles, outlining how its board and management divide responsibilities and meet disclosure obligations. The board charter emphasizes over...
SomnoMed Flags Risks and Limits of FY26 Investor Presentation
Aug 27, 2026
SomnoMed has released an investor presentation on its full-year 2026 results, framed as a high-level summary rather than a comprehensive account of its financial position, performance, or the rights and obligations attached to its securities. The ...
SomnoMed lifts FY26 earnings and expands capacity amid FX headwinds
Aug 27, 2026
SomnoMed reported FY26 revenue of $114.5 million, up 3% on the prior year, and EBITDA of $10.9 million, a 19% increase that lifted its EBITDA margin to 9.6% through disciplined cost control. A stronger Australian dollar and shifting European marke...
SomnoMed narrows annual loss as revenue edges higher in FY2026
Aug 27, 2026
SomnoMed Limited, a specialist in clinically proven oral appliance therapies for sleep-related breathing disorders, reported modest revenue growth for the year ended 30 June 2026 despite remaining loss-making. The company continues to leverage its...
SomnoMed Options Lapse, Trimming Potential Share Dilution
Aug 25, 2026
SomnoMed Limited has announced the cessation of a portion of its issued capital, with 233,000 SOMAB options and 1,242,000 SOMAA options expiring on 25 August 2026.The options, both due to expire in June 2027 with exercise prices of $2.33 and $2.00...
SomnoMed Sets Date for FY26 Results and Investor Webinar
Aug 19, 2026
SomnoMed Limited, a specialist in clinically proven oral appliance therapies for sleep-related breathing disorders, has built a global footprint with its SomnoDent device, serving more than one million patients in over 20 countries. The company...
Somnomed Discloses Equity Holdings as Director Amrita Singh Blickstead Departs Board
Jul 27, 2026
Somnomed Limited has reported a change on its board, noting that director Amrita Singh Blickstead ceased to be a director on 27 July 2026. The filing details her remaining interests in the company, including 2,392,364 ordinary fully paid shares, 1...
SomnoMed reshapes leadership, tempers FY26 revenue and launches Virtus for OSA bruxism segment
Jul 27, 2026
SomnoMed has announced a leadership transition, with Co-CEO and Executive Director Amrita Blickstead stepping down and fellow Co-CEO Karen Borg moving into the sole CEO role. The board credited Blickstead with driving operational improvements and ...
Somnomed Director Karen Borg Updates Share and Option Holdings
Jul 24, 2026
Somnomed Limited has reported a change in the relevant interests of director Karen Borg, following the exercise of options that altered her holdings in the company’s securities. The notice details that Borg’s interests include both dir...
SomnoMed Seeks ASX Quotation for 575,000 New Shares
Jul 24, 2026
SomnoMed Limited has applied for quotation on the ASX of 575,000 new fully paid ordinary shares, issued on 23 July 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, and will...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.